Revvity, Inc. (RVTY) Earnings Call Transcripts

Revvity, Inc.'s Latest Earnings Call - Q2 FY2026

In Q2 2026, Revvity, Inc. (RVTY:US) reported total revenue of $711 million, reflecting a pro forma organic growth of 3%, slightly above the high end of guidance. Adjusted EPS came in at $1.41, exceeding expectations primarily due to better-than-anticipated operating performance and tariff refunds. Management raised full-year guidance for organic growth to 4%-5% from 3%-4%, and adjusted EPS guidance increased by $0.10 to a range of $5.30 to $5.40, indicating a positive outlook for the remainder of the fiscal year.

Reported metrics

Guidance from management

Management raised full-year organic growth guidance to 4%-5% from 3%-4% and adjusted EPS guidance to $5.30-$5.40, reflecting improved market conditions and operational performance.

What management said

Yes, I would just say for some of the numbers specifics, if you look at the second quarter performance from a Life Sciences perspective, we had positive growth in both our reagents and platforms business. I think as you look at the full year outlook, we are now anticipating an uptick in our platform's performance for the full year. Previously, we were assuming positive low single-digit growth for our platforms busine...

Yes, Vijay. So I think as you look at the EPS guidance for the full year, again, we took up $0.10 at the midpoint. That $0.10 raise is half of the net tariff of reinvestments that we are flowing through for the full year. And then the other half is due to the incremental contribution from the higher organic growth for the full year. And I think when you do the math on the incremental margins there, you're right aroun...

What analysts pressed on

Analysts expressed concerns regarding the significant decline in the Signals software business and questioned the sustainability of growth in the Diagnostics segment. There were also inquiries about the impact of AI on future revenue growth and the timing of backlog conversions into sales.

Main topics on the call

• Revenue Growth Acceleration — Revvity achieved total revenue of $711 million in Q2 2026, driven by a 3% organic growth rate. Management noted, "Our pro forma organic growth of 3%... resulted in total revenue being above the high end of our expectatio...
• Strong Diagnostics Performance — The Diagnostics segment grew 11% organically, reflecting robust demand in reproductive health and immunodiagnostics. Prahlad Singh stated, "The consistency and durability of this franchise continues to be a defining stre...
• AI-Driven Demand — Management highlighted increasing orders from both traditional and nontraditional customers related to AI-driven drug discovery, stating, "We are seeing a definitive and progressively larger increase in orders directly r...
• Software Segment Challenges — The Signals software business experienced a 20% organic revenue decline year-over-year. However, management anticipates a return to double-digit growth in the second half, indicating recovery potential.

Read the full Revvity, Inc. transcript (Q2 FY2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 90 Revvity, Inc. earnings call transcripts on record, spanning January 14, 2020 to August 4, 2026. Based on this history, Revvity, Inc. reports quarterly. The most recent call on file is dated August 4, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

RVTY

Exchange

NYSE

Country

US

Sector

Health Care

Industry

Life Sciences Tools and Services

Calls on record

90

First call

January 14, 2020

Most recent

August 4, 2026

Reporting cadence

quarterly